ENTO_OUT_1 [2025-04-03 16:50:42 -0400] 3096 Bytes | 793 tokens | Cum: 793 tkns (9.91% of 8k)
==========================================================================

We're scouting for winners today. Its 4:50:41 PM on Thu Apr 03, 2025 -0400 and I'm looking at Entero Therapeutics (ENTO) up to 0.943 from 0.4111

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Entero Therapeutics (ENTO)
IPO: 2016-10-11 (8 Years Ago)
Market Cap: $1,949,152
Shares Outstanding: 4,750,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Here's the first list of news for Entero Therapeutics:

C1 - Mar-24-25 10:51PM - Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
C2 - Feb-14-25 04:00PM - Entero Therapeutics Appoints Richard Paolone as CEO
C3 - Feb-07-25 03:22PM - Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
C4 - Nov-14-24 08:00AM - Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum
C5 - Nov-13-24 07:00AM - Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
C6 - Sep-10-24 07:00AM - Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
C7 - Aug-23-24 05:00PM - Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q
C8 - Jul-31-24 07:00AM - Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Entero Therapeutics (ENTO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ENTO_OUT_3 [2025-04-03 16:50:46 -0400] 1098 Bytes | 299 tokens | Cum: 1094 tkns (13.68% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC**
Date: Mar-24-25 10:51PM
Source: (Newsfile)
URL: https://www.newsfilecorp.com/release/245950/Entero-Therapeutics-Announces-Signing-of-Rescission-Agreement-with-ImmunogenX-LLC

We use cookies to analyze user behavior in order to constantly improve the website for you.Learn more.

Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous shareholders of ImmunogenX, LLC ("IMGX") in relation to the ImmunogenX Business Combination which was previousl

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTO_OUT_5 [2025-04-03 16:50:47 -0400] 1018 Bytes | 284 tokens | Cum: 1442 tkns (18.02% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-25T03:06:05Z - Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC By Investing.com...
A2 - 2025-03-25T03:06:05Z - Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC By Investing.com...
A3 - 2025-03-25T03:04:04Z - Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC By Investing.com...
A4 - 2025-03-25T03:02:00Z - Entero Therapeutics, Inc.: Entero Therapeutics Announces Signing of Rescission Agreement with Immuno...
A5 - 2025-03-25T02:57:02Z - Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ENTO_OUT_7 [2025-04-03 16:50:47 -0400] 1098 Bytes | 303 tokens | Cum: 1747 tkns (21.84% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC By Investing.com**Date: 2025-03-25Source: {'uri': 'za.investing.com', 'dataType': 'news', 'title': 'Investing.com South Africa'}URL: https://za.investing.com/news/press-releases/entero-therapeutics-announces-signing-of-rescission-agreement-with-immunogenx-llc-93CH-3623102Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous shareholders of ImmunogenX, LLC ("IMGX") in relation to the ImmunogenX Business Combination which was previously announc

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTO_OUT_9 [2025-04-03 16:50:48 -0400] 1095 Bytes | 348 tokens | Cum: 2097 tkns (26.21% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-14T21:00:00Z - Entero Therapeutics Appoints Richard Paolone as CEO
B2 - 2024-12-06T17:00:00Z - $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF
B3 - 2024-11-16T16:42:00Z - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, LBRDA, ENTO, LLYVA on Behalf of Shareholders
B4 - 2024-11-15T22:58:00Z - $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO
B5 - 2024-11-13T12:00:00Z - Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company
B6 - 2024-08-23T21:00:00Z - Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ENTO_OUT_11 [2025-04-03 16:50:52 -0400] 979 Bytes | 260 tokens | Cum: 2359 tkns (29.49% of 8k)
==========================================================================

Showing B5 (chunk 1 of 1): B5:
**Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/13/2980077/0/en/Entero-Therapeutics-Announces-Proposed-Reverse-Merger-with-Journey-Therapeutics-A-Clinical-Stage-First-in-Class-Next-Generation-ADC-rivalling-Nano-immunoconjugates-Biopharmaceutica.htmlEntero Therapeutics and Journey Therapeutics announce a proposed reverse merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Journey's next-gen, first-in-class nano-immunoconjugates platform and Entero's gastrointestinal product pipeline.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTO_OUT_13 [2025-04-03 16:50:53 -0400] 1083 Bytes | 289 tokens | Cum: 2730 tkns (34.12% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-01 10-K ITEM 7.

MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

##TABLE_END

You should read the following discussion and analysis in conjunction with our CONS financial statements, including the notes thereto contained in this Annual Re...

S2 - 2025-03-25 8-K Item 1.01. Entry Into a Material Definitive Agrmt

Rescission Agrmt

As previously disclosed on the Curr Report on Form 8-K filed with the Securities and Exchange Commission on March 14, 2024, Entero Therapeutics, Inc. (the Company) entered into and consummated trans...

S3 - 2025-02-14 8-K Item 7.01 Regulation FD Disclosure.

On February 14, 2025, the Company issued a press release announcing Mr. Paolones appointment as Interim Chf Exec Off. The press release is attached hereto as Exhibit 99.1.

The information furnished in Item 7.01 of this Curr Rep...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ENTO_OUT_15 [2025-04-03 16:50:57 -0400] 1098 Bytes | 237 tokens | Cum: 2969 tkns (37.11% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

##TABLE_END

You should read the following discussion and analysis in conjunction with our consolidated financial statements, including the notes thereto contained in this Annual Report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of certain factors, including those set forth under Risk Factors Associated with Our Business and elsewhere in this Annual Report.

Overview

We are engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal ( GI ) diseases. Non-systemic therapies are non-absorbable drugs that act locally, i.e., in the intestina

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ENTO_OUT_17 [2025-04-03 16:51:07 -0400] 4437 Bytes | 1176 tokens | Cum: 4243 tkns (53.04% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 5,757,619 | Perf Month: -22.63% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 231.29K | Perf Quarter: -29.74% | Short Float: 3.06% | ROE: -51.50% |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 24.89 | Index: - | Short Ratio: 0.62 | ROI: -31.69% |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 41.49 | Market Cap: 2.08M | Short Interest: 0.14M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.07 | Shs Outstand: 4.75M | Beta: 0.79 | EPS Surprise: 149.35% |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: -14.08% | Shs Float: 4.66M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: -14.56% | Inst Own: 1.52% | Sales past 5Y: 0.00% | Earnings: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: -28.91% | Insider Own: 1.97% | Employees: 2 | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: -18.32% | Insider Trans: -1.27% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

No transactions recorded.

No transactions recorded.

Inside Trans: Entero Therapeutics, Inc. (ENTO) by Romano Sarah (Chief Financial Officer) on 2025-01-06
- Common Stock: 727 shares at $0.64 (D) Footnote: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -2580971.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.437
Average Volume: 371997.87
30-Day High: 0.606
30-Day Low: 0.410102

[Detailed Financials: Q3 2024]
- Total Assets: $85,820,620.0
- Total Liabilities: $15,770,517.0
- Total Equity: $8,369,003.0
- Current Assets: $83,842,258.0
- Current Liabilities: $15,690,304.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.59

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: N/A
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ENTO_OUT_19 [2025-04-03 16:51:09 -0400] 676 Bytes | 167 tokens | Cum: 4672 tkns (58.40% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ENTO_IN_21 [2025-04-03 16:51:09 -0400] 126 Bytes | 29 tokens | Cum: 4729 tkns (59.11% of 8k)
==========================================================================

====================================
[2025-04-03 16:51:09] # Analysis Completed
Elapsed Time: 28.36 seconds